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Abstract
Objective—Total dose of oxytocin received during labor is an important variable in studies of 
human labor but is difficult to calculate. We sought to identify a surrogate measure for total dose 
of oxytocin received.
Study Design—For each subject receiving oxytocin during labor, the oxytocin total dose 
received in labor was calculated as the area under the curve. Maximal oxytocin infusion rate, total 
duration of oxytocin infusion, and the product of both, defined as the oxytocin product, were then 
each correlated with the total dose of oxytocin received using the Pearson’s correlation coefficient.
Results—Oxytocin dosing data were available from 402 women at Duke and 6,907 women from 
Pithagore6. The two variables alone, or combined as the oxytocin product, demonstrated a high 
correlation with the oxytocin total dose (r > 0.7), with the oxytocin product demonstrating the 
highest (r > 0.9). This was true whether labor was induced or augmented and whether delivery was 
vaginal or cesarean.
Conclusion—The oxytocin product, composed of two easily obtained variables, demonstrated a 
very high correlation with total oxytocin dose received in labor and represents a simple and 
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accurate surrogate for total dose of oxytocin received during labor. The oxytocin product can be 
used in clinical studies in which oxytocin dose is an important variable.
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Oxytocin is an endogenous hormone that is released in large amounts during spontaneous 
labor.1 In addition, synthetic oxytocin is used clinically for induction and augmentation of 
labor.2 Due to its short serum half-life and narrow therapeutic range, oxytocin infusions 
typically begin at low rates and then are incrementally increased until the rate that produces 
an appropriate uterine contractile response is achieved. The dose at which this occurs varies 
for individual women and is difficult to predict.1,3,4
The optimal oxytocin dosing regimen for induction or augmentation of labor is not known. 
Prolonged infusions of oxytocin are associated with decreased uterine contractility.5–8 
Clinically, this may present as dysfunctional labor patterns during labor, which increase the 
risk for cesarean delivery, or as uterine atony following delivery, which is an important risk 
factor for postpartum hemorrhage.9–11 The mechanism by which this occurs is thought to be 
due to oxytocin-mediated desensitization of the oxytocin receptor, but it is not known if 
prolonged infusions directly cause these adverse events or if some other predictor that 
correlates with the need for long infusions drives the association.5,12,13 Regardless, oxytocin 
exposure in labor is an important predictor of labor outcomes.
The total dose of oxytocin that a woman receives during labor is difficult to calculate as the 
infusion rate of oxytocin does not remain constant for each woman, but rather varies during 
the course of labor. The area under the curve (AUC) of oxytocin infusion rate versus 
duration of oxytocin infusion gives the total dose of oxytocin received in labor but is 
difficult to calculate. Calculating the AUC involves determining the rate of administration, 
as well as the duration of time at each rate, for the entire labor. As total oxytocin exposure 
during labor is an important clinical variable that is associated with various obstetric 
outcomes, the objective of this study was to determine if other more readily accessible 
measures of oxytocin dosing could be utilized as a surrogate for total dose of oxytocin 
received in labor.
Materials and Methods
The study was approved by the Institutional Review Board of Duke University and by the 
Sud Est III Institutional Review Board and the French Data Protection Agency (CNIL) for 
the Pithagore6 Investigators. We conducted a retrospective cohort study to determine if the 
two variables related to oxytocin dosing and utilization during labor that are readily 
available from the medical record, namely, maximal rate of infusion and duration of 
infusion, could be used as a surrogate for total dose of oxytocin received during labor.
Two independent cohorts of women for whom oxytocin dosing data were available were 
utilized for this study. The first cohort of subjects came from a retrospective cohort study 
that was conducted at the Duke University Hospital between 2009 and 2010. The study 
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included consecutive women at 36 weeks or more laboring at the Duke University Hospital 
with a live, nonanomalous fetus who received oxytocin for induction or augmentation of 
labor. The Duke study was originally designed as a quality initiative to determine oxytocin 
utilization on the Duke University Hospital labor and delivery unit. Data were abstracted 
from the medical records by two of the authors (C.A.G. and L.L.L.). The second cohort of 
subjects came from women who enrolled in the Pithagore6 trial, a cluster-randomized 
controlled trial conducted at 106 units in France between 2004 and 2006 to evaluate an 
educational intervention to reduce the rate of severe postpartum hemorrhage.14 The 
Pithagore6 trial has been previously described in detail.14 The total amount of oxytocin 
received during labor was available for 402 women from the Duke cohort and for 6,907 
women who had enrolled in the Pithagore6 study. For each subject in both cohorts, total 
dose of oxytocin in labor in mU was calculated by plotting oxytocin infusion rate versus 
time (Fig. 1) and then computing the AUC using GraphPad Prism version 6.0 (GraphPad 
Software, Inc, La Jolla, CA) for the Duke cohort and Microsoft Excel (Microsoft 
Corporation, Redmond, WA) for the Pithagore6 cohort.
For each of the two study populations, maximal rate of oxytocin infusion (in mU/min), the 
duration of oxytocin infusion (in hours), and the oxytocin product (product of maximal 
oxytocin infusion rate with total duration of infusion, mU/min × hours) were each correlated 
with total oxytocin dose received in labor (mU) using a Pearson’s correlation coefficient. 
Maximal rate of infusion was defined as the highest infusion rate of oxytocin that a subject 
received at any time during her labor. Duration of infusion was defined as the total time a 
subject received oxytocin, accounting for periods in which the infusion may have been 
discontinued during labor. Given the large sample size, differences in continuous variables 
between each cohort were compared using an unpaired t-test with Welch’s correction, which 
assumes that the standard deviations for each variable are not similar between the two 
cohorts. All statistical analyses were performed using GraphPad Prism version 6.0 
(GraphPad Software, Inc) and JMP 11 (Version 11.0, SAS Institute, Inc, Cary, NC). 
Normally distributed continuous variables were reported as mean and standard deviations, 
while nonnormally distributed continuous variables were reported as median and 
interquartile range (IQR). A p-value of < 0.05 was considered to be significant.
Results
There were 402 women from the Duke cohort with complete oxytocin data available, which 
included the maximal rate of infusion, the duration of infusion, and the total dose received. 
Of the 6,907 women from the Pithagore6 cohort with total oxytocin dosing available, 6,842 
women had oxytocin product data available. Table 1 summarizes basic subject 
characteristics from each cohort. Women from the Duke cohort were significantly younger, 
had greater body mass index at delivery, and delivered infants with smaller birth weights 
compared with women in the Pithagore6 cohort. In addition, women at Duke were more 
likely to have been induced and the Duke cohort had a higher cesarean delivery rate 
compared with women from France (Table 1).
Women in the Duke cohort received higher median maximal oxytocin infusion rates and 
longer duration of infusions, resulting in a significantly greater oxytocin product than 
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women in the Pithagore6 cohort (Table 2). Similarly, women in the Duke cohort received 
significantly greater total dose of oxytocin (median [IQR]) than women in the Pithagore6 
cohort (3,535 [1,194, 9,822] vs. 1,370 [540, 2,940] mU, p < 0.0001) (Table 2).
Maximal oxytocin infusion rate correlated well with oxytocin total dose in both the Duke 
and Pithagore6 cohorts (r = 0.79 [95% confidence interval [CI]: 0.75, 0.82] and r = 0.75 
[95% CI: 0.74, 0.76], respectively, Table 3, Fig. 2). Similarly, the duration of oxytocin 
infusion correlated well with oxytocin total dose in both groups (r = 0.73 [95% CI: 0.68, 
0.77] and r = 0.81 [95% CI: 0.80, 0.82], respectively). The oxytocin product correlated best 
with oxytocin total dose in both cohorts compared with either maximal rate of oxytocin 
infusion or duration of infusion (r = 0.95 [95% CI: 0.93, 0.96] and r = 0.93 [95% CI: 0.93, 
0.93], for the Duke and Pithagore6 cohorts, respectively, Table 3, Fig. 2).
Duration of infusion was defined as the total time that a subject received oxytocin, which 
accounted for periods in which the infusion was discontinued either during labor or prior to 
delivery. For example, among subjects for whom their oxytocin infusion was temporarily 
discontinued (i.e., for fetal intolerance of labor or to provide the laboring mother a break 
from oxytocin), the duration of infusion variable did not include the time that oxytocin was 
not being given. For the Duke cohort, the time from the initiation of oxytocin to delivery was 
also available for analysis. This variable was the period of time from the start of oxytocin 
until delivery. Similar to duration of infusion, the period of time from initiation of oxytocin 
to delivery also correlated well with oxytocin total dose (r = 0.74 [95% CI: 0.68, 0.78]) in 
the Duke cohort. In addition, when the time from initiation of oxytocin to delivery was 
included in the oxytocin product (maximal oxytocin infusion rate × time from initiation of 
oxytocin to delivery), this also correlated extremely well with oxytocin total dose (r = 0.95 
[95% CI: 0.92, 0.96]).
Both cohorts included women who received oxytocin for labor induction as well as those 
who labored spontaneously but received oxytocin for augmentation of labor. Table 4 
provides the correlations from both cohorts for the three studied variables, maximal rate of 
infusion, duration of infusion, and the oxytocin product, each compared with oxytocin total 
dose, stratified by whether oxytocin was utilized for induction or augmentation of labor 
(Table 4). Within the Pithagore6 cohort, the relationships persisted demonstrating that the 
oxytocin product correlated best with the total oxytocin dose received in labor (Table 4). 
Within the Duke cohort, which was much smaller, the 95% CIs for the Pearson’s 
correlations for the oxytocin product with oxytocin total dose overlapped with some of the 
other measures of oxytocin exposure within the subgroup analysis (Table 4). Results from 
each cohort were also stratified by mode of delivery, which also demonstrated similar 
findings (Table 4).
Comment
Oxytocin is an important clinical exposure that affects labor outcomes. Calculating the total 
dose of oxytocin that a woman receives during labor is difficult and time-consuming as the 
infusion rate is typically not constant and varies throughout her labor. Here, we demonstrate 
that the oxytocin product, the product of total duration of oxytocin infusion during labor 
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with the maximal infusion rate, correlates highly with the total dose received suggesting that 
the oxytocin product is a valid surrogate for total dose received. Importantly, the oxytocin 
product is composed of two variables, total duration received and maximal infusion rate, 
both of which are variables typically easily abstracted from the medical record.
Our data are generated from two relatively large, yet distinct patient populations. Oxytocin 
utilization, including maximal infusion rates and duration of infusion, also differed 
significantly between the two cohorts. Despite this, similar correlation findings were seen 
with each of the three studied oxytocin variables with total oxytocin dose between the two 
cohorts. Not only did oxytocin dosing differ between the two cohorts but also the 
characteristics of women and deliveries suggest that the populations may be different. 
Together, this adds strength to the association that we found of the oxytocin product with 
total oxytocin dose and suggests that the correlations would remain strong when applied to 
other populations. It is unknown if our findings are generalizable to other delivery units 
whose oxytocin utilization may differ but our study does include data from distinct patient 
populations whose oxytocin exposure differed. Finally, the oxytocin product does not 
estimate the actual total dose and thus cannot be used to estimate or predict the total 
oxytocin dosing during labor, but it can be used as a surrogate for oxytocin exposure as the 
oxytocin product highly correlates with total dosing.
We found that two variables that are easily identified in the medical record, and commonly 
collected as part of clinical obstetric research, namely, the maximal oxytocin infusion rate 
and the duration of oxytocin infusion, when combined as a product, correlate highly with the 
total amount of oxytocin received in labor. As the total dose of oxytocin received in labor is 
associated with numerous obstetric clinical outcomes, and is difficult to calculate, the 
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Graphical representative example of total oxytocin dose received in labor from a single 
subject. To calculate the total dose of oxytocin received during labor, for each woman, a plot 
must be constructed of oxytocin infusion rate with time. The shaded region, or the area 
under the curve, represents the total dose of oxytocin received during labor.
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Correlations of oxytocin maximal infusion rate, duration of oxytocin infusion, and the 
oxytocin product each with total oxytocin dose (calculated by the AUC) received in labor 
among women from Duke and Pithagore6. (A and B) Correlation of maximal oxytocin 
infusion rate with oxytocin total dose from Duke (A, r = 0.79, p < 0.0001) and Pithagore6 
(B, r = 0.75, p < 0.0001). (C and D) Correlation of duration of oxytocin infusion with 
oxytocin total dose from Duke (C, r = 0.73, p < 0.0001) and Pithagore6 (D, r = 0.81, p < 
0.0001). (E and F) Correlation of the oxytocin product (maximal infusion rate × duration of 
infusion) with oxytocin total dose from Duke (E, r = 0.95, p < 0.0001) and Pithagore6 (F, r 
= 0.93, p < 0.0001). AUC, area under the curve.
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Age, ya 27.0 ± 6.6 29.9 ± 5.2 <0.0001
Race/ethnicity, n (%) Not available
 White 129 (32.1)
 Black 149 (37.1)
 Hispanic 95 (23.6)
 Asian/Pacific Islander 22 (5.5)
 Other 2 (0.5)
 Missing 5 (1.2)
BMI, kg/m2a,b 33.0 ± 7.2 27.9 ± 4.4 <0.0001
Gestational age at delivery, wka 38.8 ± 2.4 39.8 ± 1.6 <0.0001
Induced labor, n (%) 306 (76.1) 2,115 (30.6) <0.0001
Mode of delivery, n (%)
 Vaginal 288 (71.6) 6062 (87.8) <0.0001
 Cesarean 114 (28.4) 845 (12.2)
Birthweight, ga 3,196 ± 627 3,389 ± 374 <0.0001
Abbreviation: BMI, body mass index.
a
Mean ± standard deviation.
b
BMI at delivery.





















Maximal oxytocin infusion rate, mU/min 9.0 (5.0, 16.0) 7.5 (5.0, 12.5) <0.0001
Total duration of oxytocin infusion, h 11.6 (6.4, 20.4) 4.1 (2.2, 6.3) <0.0001
Oxytocin product, mU/min × h 173 (46, 880) 32.5 (11.8, 72.6) <0.0001
Oxytocin total dose (AUC), mU 3,525 (1,194, 9,822) 1,370 (540, 2,940) <0.0001
Abbreviation: AUC, area under the curve.
a
The Duke data are from 402 women.
b
The Pithagore6 data are as follows: 6,854 women with maximal infusion rate, 6,895 women with total duration of oxytocin infusion, 6,842 
women with oxytocin product, and 6,907 with oxytocin total dose (AUC).
Note: Data presented are median (interquartile range).
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Table 3
Pearson’s correlations of oxytocin parameters with oxytocin AUC, all subjects





Maximal oxytocin infusion rate 0.79 (0.75, 0.82) 0.75 (0.74, 0.76)
Duration of infusion 0.73 (0.68, 0.77) 0.81 (0.80, 0.82)
Oxytocin product 0.95 (0.93, 0.96) 0.93 (0.93, 0.93)
Abbreviation: AUC, area under the curve.
a
All Pearson’s correlations listed had p-values of <0.0001.
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Table 4
Pearson’s correlations of oxytocin parameters with oxytocin AUC among listed clinical subgroups
Variable Pearson’s correlations (95% CI) for each listed parameter with oxytocin AUCa
Duke Pithagore6
Induced labor N = 306 N = 2,115
 Maximal oxytocin infusion rate 0.78 (0.64, 0.87) 0.76 (0.74, 0.77)
 Duration of infusion 0.84 (0.74, 0.91) 0.79 (0.78, 0.80)
 Oxytocin product 0.91 (0.84, 0.94) 0.92 (0.92, 0.93)
Spontaneous augmented labor N = 96 N = 4,792
 Maximal oxytocin infusion rate 0.85 (0.75, 0.91) 0.72 (0.69, 0.74)
 Duration of infusion 0.79 (0.65, 0.87) 0.80 (0.78, 0.81)
 Oxytocin product 0.92 (0.87, 0.96) 0.92 (0.91, 0.93)
Vaginal delivery N = 288 N = 6,062
 Maximal oxytocin infusion rate 0.78 (0.65, 0.87) 0.75 (0.74, 0.76)
 Duration of infusion 0.87 (0.78, 0.92) 0.81 (0.80, 0.82)
 Oxytocin product 0.96 (0.93, 0.98) 0.93 (0.92, 0.93)
Cesarean delivery N = 114 N = 845
 Maximal oxytocin infusion rate 0.81 (0.68, 0.89) 0.77 (0.74, 0.80)
 Duration of infusion 0.87 (0.77, 0.92) 0.82 (0.80, 0.84)
 Oxytocin product 0.93 (0.87, 0.96) 0.93 (0.92, 0.93)
Abbreviation: AUC, area under the curve.
a
All Pearson’s correlations listed had p-values of <0.0001.
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